Zacks Investment Research on MSN
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...
Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...
The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication in adults and ...
Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® ...
Omeros transitions from a distressed microcap to a small-cap following a transformative Novo Nordisk deal and FDA approval of ...
Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...
Stocktwits on MSN
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug
Omeros said it had resubmitted its FDA application for Narsoplimab in March 2025, with the PDUFA target date later extended ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
The Dow Jones Industrial Average climbed 0.6% to 48,731.16, while the S&P 500 added 0.32% to close at 6,932.05.
Omeros, one of Seattle’s biggest biotech companies, may have its hands on a lucrative new drug — but questions about the drug and how it has been studied, first raised by an anonymous report, continue ...
Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. The stock was up 78% to $15.60 on Wednesday and was briefly paused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback